ImmuCell Co. (NASDAQ:ICCC - Get Free Report)'s stock price passed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $4.99 and traded as high as $6.65. ImmuCell shares last traded at $6.52, with a volume of 20,435 shares.
ImmuCell Price Performance
The company has a quick ratio of 1.44, a current ratio of 3.11 and a debt-to-equity ratio of 0.36. The stock has a market cap of $57.29 million, a price-to-earnings ratio of -12.68 and a beta of 0.23. The company's 50-day moving average is $5.41 and its 200-day moving average is $5.05.
ImmuCell (NASDAQ:ICCC - Get Free Report) last released its quarterly earnings results on Wednesday, May 14th. The biotechnology company reported $0.16 EPS for the quarter. ImmuCell had a negative net margin of 15.99% and a negative return on equity of 15.32%. The business had revenue of $8.07 million for the quarter.
Hedge Funds Weigh In On ImmuCell
A number of hedge funds and other institutional investors have recently bought and sold shares of ICCC. Mesirow Financial Investment Management Inc. boosted its stake in ImmuCell by 100.0% in the fourth quarter. Mesirow Financial Investment Management Inc. now owns 24,356 shares of the biotechnology company's stock valued at $125,000 after acquiring an additional 12,178 shares during the last quarter. Citadel Advisors LLC bought a new position in ImmuCell in the fourth quarter valued at approximately $149,000. Northern Trust Corp boosted its stake in ImmuCell by 51.0% in the fourth quarter. Northern Trust Corp now owns 44,374 shares of the biotechnology company's stock valued at $229,000 after acquiring an additional 14,982 shares during the last quarter. Geode Capital Management LLC boosted its stake in ImmuCell by 13.9% in the fourth quarter. Geode Capital Management LLC now owns 64,538 shares of the biotechnology company's stock valued at $332,000 after acquiring an additional 7,878 shares during the last quarter. Finally, Dauntless Investment Group LLC bought a new position in ImmuCell in the fourth quarter valued at approximately $676,000. 13.47% of the stock is owned by institutional investors.
ImmuCell Company Profile
(
Get Free Report)
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E.
Further Reading
Before you consider ImmuCell, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImmuCell wasn't on the list.
While ImmuCell currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
